Evaluation of the Use of Trastuzumab to Induce Increased ER Expression in ER-Negative/Low, Her-2/Neu Positive Breast Cancer
- Women who have Her-2 positive and ER- negative or ER-low breast cancer that has not
metastasized, or spread to other parts of the body, are eligible for the study.
- Participants must have had either a core biopsy or incisional biopsy of their breast
cancer, but not yet had definitive breast surgery, including lumpectomy or
- Participants may not have had a BRCA mutation found on genetic testing.
- Participants should have not yet received treatment for their breast cancer,
- hormonal therapy,
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To see if treatment with trastuzumab can make ER appear in ER "negative" breast cancer.Trastuzumab is an anti-Her-2 drug usually given after surgery for treatment of Her-2 "positive" breast cancer.
Outcome Time Frame:
Anne Schott, MD
University of Michigan Cancer Center
United States: Institutional Review Board
- Breast Cancer
- Breast cancer
- not metastasized
- Breast Neoplasms
|University of Michigan Comprehensive Cancer Center
||Ann Arbor, Michigan 48109-0752